

Parkinson Disease

Neurodegeneration · molecular mechanisms · morphology · clinical correlation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Teaching objectives

- Explain how nigrostriatal dopamine loss produces parkinsonism.
- Compare major genetic and cellular mechanisms implicated in PD.
- Recognize substantia nigra depigmentation, Lewy bodies, and Lewy neurites.
- Connect pathology to clinical features, progression, and treatment limits.

Parkinson disease is more than parkinsonism


Disease

- Parkinson disease is a neurodegenerative disease.
- Loss of substantia nigra dopaminergic neurons causes the motor syndrome.
- Pathology also affects nuclei beyond the nigrostriatal system.

Syndrome

- Parkinsonism describes a recognizable movement syndrome.
- It may follow PD, dopamine-receptor antagonism, toxins, or other disorders.
- A syndrome alone does not identify the underlying disease.


The central clinicopathologic pathway



The pathway explains the dominant motor abnormalities. • Other involved brain regions help explain nonmotor and cognitive consequences.


The nigrostriatal circuit

Relatively preserved



More nigral neurons → dopamine input

Degenerated in PD



Fewer neurons → less dopamine

Loss of neurons in the substantia nigra reduces dopaminergic innervation of the striatum.

Motor manifestations form a recognizable constellation

Movement

Slowing of voluntary movement

Tone / rhythm

Rigidity and pill-rolling tremor

Posture / gait

Stooped posture and festination


Face

Diminished facial expression

Bradykinesia: Slowing of movement

- Bradykinesia denotes abnormally slow voluntary movement.
- It is one component of the core clinical triad used.
- It reflects dysfunction of the nigrostriatal dopaminergic system.
- The clinical finding is not, by itself, specific for PD.

Festinating gait



Festination as progressively shortened, accelerated steps with forward leaning. • A characteristic gait supports the syndrome, not necessarily a unique cause.

Parkinsonism has multiple etiologies


Parkinson disease

- Neurodegeneration of nigral dopaminergic neurons.
- Typical Lewy pathology in many affected neurons.
- Progression may involve brainstem, limbic system, and cortex.

Other causes

- Dopaminergic antagonists may induce symptoms.
- Some toxins selectively injure the dopamine system.
- Other neurodegenerative disorders can include parkinsonism.

Dopamine antagonism can mimic PD




Textbook distinction: A drug-induced phenotype is not equivalent to established idiopathic PD. •
Review exposure history when evaluating parkinsonism.

MPTP: A selective dopaminergic neurotoxin

- MPTP is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- An illicitly synthesized meperidine contaminant was linked to acute parkinsonism.
- Exposure can destroy substantia nigra neurons.
- The resulting motor syndrome illustrates vulnerability of the dopaminergic system.

Why MPTP matters experimentally



MPTP exposure provides an experimental model of nigrostriatal injury. • Animal models of this type have been used to test therapies.

Pesticide exposure is an epidemiologic signal

- Epidemiologic evidence associating pesticide exposure with increased PD risk.
- An association does not establish a specific causal mechanism for every exposure.
- Environmental susceptibility and inherited susceptibility are distinct questions.
- The observation supports investigation of environmental contributions.

Protective associations are not treatment advice

Source-reported associations

- Caffeine exposure appears protective in epidemiologic studies.
- Nicotine exposure also appears protective in epidemiologic observations.

Interpretive limit

- Observational associations do not establish prevention or treatment efficacy.
- The textbook description is not a recommendation to use nicotine.

Most PD is sporadic

- Sporadic disease is the predominant presentation.
- Familial cases have identified genes relevant to pathogenic mechanisms.
- Mutations can illuminate protein aggregation, mitochondrial quality control, and lysosomal biology.
- Mechanistic relevance does not imply every sporadic case carries the same mutation.

Three converging mechanisms

Protein homeostasis

α -synuclein accumulation and oligomer toxicity

Mitochondrial integrity

Stress responses and defective mitophagy

Lysosomal clearance

Disruption of autophagy–lysosome function

Signaling regulation

LRRK2 kinase and Rab-protein phosphorylation

SNCA encodes α -synuclein

- SNCA encodes α -synuclein, a lipid-binding protein abundant at synapses.
- α -Synuclein is a major molecular component of Lewy bodies.
- Inherited SNCA mutations established a direct genetic link to PD.
- This relationship connects a synaptic protein to neuronal aggregate pathology.

SNCA pathogenic alterations


Sequence-level changes

- Rare inherited point mutations affect SNCA.
- Certain mutations cause autosomal dominant PD.

Copy-number / dosage


- Amplification of the SNCA-containing region on chromosome 4q21 is described.
- Increased gene dosage is another route to α -synuclein-associated PD.

Aggregation is not a single molecular state




The source specifically points to small α -synuclein oligomers as apparently most toxic to neurons. • Visible Lewy bodies and the implicated toxic molecular species should not be conflated.

A proposed neuron-to-neuron spread mechanism



A prion-like pattern of propagation is suggested by experimental observations. • Present this as evidence supporting a model—not proof that all PD follows an identical route.

The anatomic progression model



Schematic of a described pattern of aggregate distribution; Not a mandatory staging rule for every patient.

Anatomic sequence and causality are different

Observed / described

- Aggregates may appear in medulla and contiguous ascending regions.
- Lewy bodies and neurites can occur in multiple neuronal populations.

Interpretation

- Intercellular propagation is a plausible explanation.
- The extent to which spreading itself causes degeneration is not fully resolved.

Mitochondrial dysfunction in PD


- Inherited PD genes implicate mitochondrial homeostasis.
- DJ-1, PINK1, and Parkin are linked to autosomal recessive PD.
- Normal mitochondrial quality control limits persistence of damaged organelles.
- Defects in this machinery offer a route to neuronal injury.

DJ-1 contributes to the stress response



DJ-1 also has other cellular roles, including transcriptional regulation. • Pathogenic alteration of DJ-1 is one genetic link between oxidative stress responses and PD.

PINK1 identifies dysfunctional mitochondria




PINK1 localizes to the outer membrane of dysfunctional mitochondria. • It recruits and phosphorylates Parkin, leading toward mitophagy.

Parkin is an E3 ubiquitin ligase

- PINK1-dependent phosphorylation activates Parkin.
- Parkin functions as an E3 ubiquitin ligase.
- Activated Parkin ubiquitinates mitochondrial proteins.
- Those tags help identify damaged mitochondria for autophagic clearance.

The PINK1–Parkin mitophagy pathway



Mitophagy is selective autophagic degradation of mitochondria. • The pathway normally prevents persistence of dysfunctional mitochondria.

PINK1 or Parkin defects disrupt clearance

Functioning pathway

- PINK1 senses a dysfunctional mitochondrion.
- Parkin is recruited and activated.
- Ubiquitinated organelle proteins support mitophagy.

Genetic defect

- PINK1 or Parkin mutation impairs the pathway.
- Damaged mitochondria are less effectively cleared.
- Mitochondrial dysfunction can persist and contribute to injury.


Complex I is reduced in sporadic PD brains

- Reduced mitochondrial complex I levels in brains with sporadic PD.
- Complex I participates in oxidative phosphorylation.
- This observation links mitochondrial abnormalities with nonfamilial disease.
- An observed reduction alone does not specify which molecular defect initiated the disease.

GBA1 changes PD susceptibility

- GBA1 encodes the lysosomal enzyme glucocerebrosidase.
- Heterozygous GBA1 mutations are an important genetic risk factor for PD.
- The textbook attributes approximately 5% of PD cases to this genetic association.
- Biallelic pathogenic GBA1 variants can cause Gaucher disease.

Lysosomal function connects metabolism to PD



The genetic link implicates the autophagy–lysosome pathway. • The precise route from risk variant to selective neuronal injury is multifactorial.

Candidate consequences of GBA1 dysfunction

α -Synuclein

Abnormal metabolism / clearance

Autophagy

Impaired degradative flux

Proteostasis

Unfolded protein response activation


Inflammation

Increased inflammatory signaling

LRRK2 encodes a cytoplasmic kinase

- LRRK2 mutations can cause autosomal dominant PD.
- Certain pathogenic variants increase LRRK2 kinase activity.
- LRRK2 variants also occur in apparently sporadic late-onset disease.
- The pathway does not reduce to α -synuclein accumulation alone.

LRRK2 and Rab phosphorylation



Robbins implicates small GTPase Rab proteins as relevant substrates. • The subsequent connection to α -synuclein accumulation and neuron loss remains incompletely explained.

Separate LRRK2 evidence from open questions

Established in source

- Some pathogenic LRRK2 variants elevate kinase activity.
- Rab hyperphosphorylation is implicated in PD pathogenesis.


Not yet resolved

- The exact causal route from Rab phosphorylation to degeneration is not elucidated.
- Do not diagram a fully proven linear pathway to neuron death.

Genetic routes are not interchangeable

Gene / factor	Inheritance or association	Key mechanistic link
SNCA	Autosomal dominant (rare)	α -Synuclein aggregation
PINK1 / PRKN	Autosomal recessive	Mitochondrial mitophagy
PARK7 (DJ-1)	Autosomal recessive	Stress / mitochondria
GBA1	Heterozygous risk factor	Autophagy–lysosome
LRRK2	Autosomal dominant	Kinase / Rab signaling


Different genes converge on neuronal vulnerability



Genetic pathways offer complementary, not mutually exclusive, explanations. • The final shared histologic effect includes neuronal loss and gliosis.


Gross pathology: Substantia nigra pallor

Reference appearance



Numerous pigmented neuronal profiles

PD — depigmentation



Fewer pigmented neuronal profiles


Macroscopic depigmentation reflects loss of neuromelanin-containing catecholaminergic neurons.

Conceptual schematic; Not anatomic gross specimens.

The locus ceruleus may also be pale

- The locus ceruleus contains pigmented catecholaminergic neurons.
- Loss of these neurons produces pallor in PD.
- The finding demonstrates pathologic involvement outside the substantia nigra.
- Gross pallor and microscopic neuronal depletion are causally linked.


What a Lewy body is



Rounded to elongated cytoplasmic eosinophilic inclusion in a surviving neuron; Often a dense center with a pale halo.

Schematic — not a histologic specimen

Lewy-body components and architecture




The ultrastructural description explains the dense core and lighter rim seen in many inclusions. •
Morphologic inclusions identify a lesion, not the full molecular mechanism of toxicity.

Lewy bodies occur in surviving neurons

- One neuron may contain a single or multiple Lewy bodies.
- Inclusions are cytoplasmic rather than nuclear.
- They may be round or elongated and intensely eosinophilic.
- Residual pigmented neurons in affected nuclei are important sites to examine.

Lewy neurites are abnormal neuronal processes



Lewy neurites are dystrophic processes containing aggregated α -synuclein.

Schematic — not a histologic specimen

The distribution of Lewy pathology is broad

Substantia nigra

Residual dopaminergic neurons

Locus ceruleus

Additional brainstem nucleus


Dorsal motor nucleus of vagus

Another brainstem site

Basal nucleus of Meynert

Cholinergic neurons

Neuronal loss is accompanied by gliosis



Gliosis often accompanies areas of neuronal depletion. • Neither gliosis nor Lewy pathology should be interpreted without anatomic context.

The clinical diagnosis uses a classic triad

Bradykinesia

Slow movement


Rigidity

Increased resistance to
movement

Tremor

Classically pill-rolling

Clinical context helps distinguish causes



The Robbins text emphasizes the classic triad in the absence of a known toxic or other underlying etiology. • A motor phenotype alone does not prove a specific neuropathology.

Pathologic signature is not a bedside test


At the bedside

- Movement slowing, rigidity, tremor, posture and gait.
- Clinical history helps identify drug or toxin exposure.

In nervous tissue

- Nigral cell loss, depigmentation and gliosis.
- Lewy bodies / neurites support an α -synuclein proteinopathy.

PD pathology can extend beyond motor nuclei




Conceptual sequence drawn from the textbook; Clinical patterns may vary.

Cortical involvement can impair cognition

- PD is not necessarily confined to the basal ganglia.
- Neocortical involvement is associated with cognitive impairment.
- Lewy pathology may extend into cortical and limbic neurons.
- PD and dementia with Lewy bodies occupy a related α -synuclein disease spectrum.

Why L-DOPA can improve motor symptoms



Motor impairment severity correlates with dopamine deficiency. • L-DOPA can improve motor symptoms, especially early in the disease.

Symptomatic improvement is not neuroprotection

What L-DOPA addresses

- Replaces a biochemical deficit in dopamine signaling.
- Can initially improve the motor phenotype.

What it does not address

- Does not arrest ongoing neurodegenerative progression.
- Does not directly eliminate all widespread nonmotor pathology.

Why therapy becomes less effective over time

- PD continues to progress despite dopamine replacement.
- The affected neuronal systems are more extensive than the nigrostriatal pathway.
- Increasing difficulty managing motor symptoms over time.
- Drug response is not equivalent to reversal of the disease process.

Deep brain stimulation is symptomatic therapy

- Deep brain stimulation can treat selected motor symptoms of PD.
- It represents a therapeutic approach distinct from dopamine precursor replacement.
- Benefit for motor manifestations.
- The text does not establish that stimulation halts the underlying neurodegeneration.

PD and dementia with Lewy bodies overlap

PD-centered presentation

- Motor parkinsonism predominates clinically.
- Cognitive decline can emerge as cortical disease develops.
- Nigral loss and Lewy pathology are prominent.

DLB-centered presentation

- Cognitive manifestations may be the presenting concern.
- Widespread cortical and brainstem Lewy pathology can occur.
- Both belong to an α -synuclein disease spectrum.

Atypical parkinsonian syndromes are not PD

Parkinson disease

- Classic nigrostriatal motor phenotype.
- Often initially responsive to L-DOPA.
- Lewy body α -synuclein pathology in typical cases.

Atypical parkinsonism

- Additional neurologic signs are prominent.
- In general, little response to L-DOPA.
- PSP/CBD are tauopathies; MSA is a glial synucleinopathy.

Pathology separates major Parkinson-plus disorders

Syndrome	Prominent clinical feature	Main pathologic protein / site
PSP	Eye movement difficulty; early falls	Tau, neuronal and glial
CBD	Asymmetric motor disturbance; apraxia	Tau, especially cortex
MSA	Autonomic dysfunction / ataxia	α -Synuclein, oligodendroglia
Typical PD	Bradykinesia, tremor, rigidity	α -Synuclein, neuronal Lewy bodies

Case: Progressive hypokinetic movement syndrome

Clinical vignette

An adult develops progressively slowed movements, reduced facial expression, rigidity, a pill-rolling tremor, and short accelerating steps.

Which disrupted neural system most directly explains the motor phenotype?

Reasoning: The substantia nigra-to-striatum dopaminergic system; Loss of nigral neurons reduces striatal dopamine.

Case: An unexpected etiologic clue

Clinical vignette

An individual develops new rigidity and bradykinesia after exposure to a dopamine-receptor antagonist.

Why is the parkinsonian phenotype insufficient to establish idiopathic PD?

Reasoning: Dopamine antagonism can produce a similar syndrome without demonstrating primary idiopathic neurodegeneration.

Case: A molecular mechanism of inherited PD

Clinical vignette

A familial PD-associated variant impairs PINK1-dependent recruitment and activation of Parkin at damaged mitochondria.


Which cellular quality-control process is most directly affected?

Reasoning: Mitophagy: Ubiquitin-dependent targeting and autophagic clearance of dysfunctional mitochondria.

Integrating genotype, morphology, and clinical signs

Biologic level	Example	Consequence
Gene / protein	SNCA → α -synuclein	Aggregate pathology
Cellular system	PINK1 / Parkin	Mitophagy impairment
Gross / tissue	Nigral neuron loss	Pallor + gliosis
Circuit / function	Striatal dopamine depletion	Hypokinetic motor signs
Progression	Extra-nigral pathology	Possible cognitive impairment

The unifying clinicopathologic model



Lewy bodies are hallmark lesions in typical PD, but molecular and anatomic processes are broader. •
Treatments improve symptoms without abolishing the underlying progression.

Essential morphology to recognize

Gross specimen

Pale substantia nigra and locus ceruleus

H&E pattern

Eosinophilic cytoplasmic Lewy inclusion with pale halo

Proteinopathy

α -Synuclein aggregates in Lewy bodies / neurites

Background tissue

Neuronal depletion with gliosis

What the source establishes—and what remains open

Supported by Robbins

- Loss of nigral dopaminergic neurons explains major motor signs.
- SNCA, mitophagy, lysosome and LRRK2 genes illuminate disease biology.
- Typical morphology includes neuronal loss, pallor and Lewy pathology.

Mechanistic uncertainty

- Relative contributions of individual pathways to every sporadic case.
- A fully proven neuron-to-neuron propagation mechanism.
- The exact pathway from abnormal LRRK2–Rab signaling to neuron death.

Primary reading

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 28: The Central Nervous System; “Parkinson Disease.”

Related textbook context: “Dementia with Lewy Bodies” and “Atypical Parkinsonian Syndromes.”

Teaching diagrams in this lecture are original, editable schematics—not clinical photographs or histologic specimens.